Saturday, July 11, 2020

New medication to prevent CMV for organ transplant recipient?

Let’s come back to Letermovir. It has also obtained the status of Orphan Drug in the European Union (EU). That status is reserved for drugs used to treat rare disease that affects a minority of the population. The drug company is given tax breaks and marketing exclusivity for 7 years in the US and 10 years in EU. This is an incentive that was created by the governments to incite drug companies to develop medicine against rare disease. CMV is known to affect less than 200,000 people in the US, most of them being organ transplant patients.

Valcyte has been on the market for 10 years and Letermovir seems to be the most serious alternative to date. With clinical trials underway we should know soon if this drug has a bright future in helping organ transplant recipients.

Pierre Luc Charland
Pierre Luc Charland
Aside from being a very experienced transplant coordinator in the Houston area, Pierre is also an amazing content creator for our properties. Pierre plays a key role in driving our mission and offering expert insight to the ever evolving world of transplantation.

Facebook Comments


Must Read

Elliot Kaye needs a kidney transplant. Then the pandemic hit.

Transplant News Sharing // News from Source I met Elliot years ago when he was the chairman of the U.S. Consumer Product Safety Commission,...

Xvivo Perfusion publ : In the starting blocks for heart preservation and PrimECC trial

Transplant News Sharing // News from Source SECOND QUARTER 2020 (APRIL-JUNE)Financial information · Net sales of non-durable goods in the quarter amounted to...

Mint Hill family anxiously wait out pandemic for organ transplant

Transplant News Sharing // News from Source PHOTO | SHARON EVANS Traci Evans Simmons (center), with husband Bruce and daughter Brielle, is on a waiting...